Definitive Contract HHSO100201600009C

Award Date 6/17/16
Potential Completion Date 9/30/26
Potential Value $282M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed

This is a $282,450,108.67 federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cerus Corporation. The contract is for the development and implementation of Cerus's proprietary pathogen reduction technology (PRT) known as the INTERCEPT Blood System. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components, helping to reduce the risk of transfusion-transmitted infections. The contract does not have a set-aside designation. Cerus Corporation is a biomedical company that has consistently secured federal contracts for its innovative blood safety solutions, providing items such as INTERCEPT processing sets and illuminators to agencies like the Defense Health Agency, Department of Veterans Affairs, and Department of Health and Human Services. This contract represents an ongoing effort to further advance Cerus's pathogen reduction technology for use in military and civilian healthcare settings.

Generated 12/14/24, 9:01 AM